ODM recommended by internatio

RNS Number : 5861C

Deltex Medical Group PLC

17 November 2009

 



Deltex Medical Group plc

ODM recommended by influential international clinical group

17 November 2009 - Deltex Medical Group plc ("Deltex Medical" "Company" or "Group"), the global leader in oesophageal Doppler monitoring ("ODM"), today announces that ODM has been recommended by the Enhanced Recovery After Surgery ('ERAS") group in their updated consensus guidelines for optimal perioperative care in colorectal surgery.

The latest ERAS consensus guideline on peri-operative fluid management in colorectal surgery state:

"Intraoperative goal-directed therapy (eg, with transesophageal Doppler monitoring) is superior to a non-protocol-based standard with respect to outcome (grade A) and should be considered on an individual basis."

The justification given for this recommendation is:

"Intraoperative transesophageal Doppler monitoring helps titrate fluids in relation to cardiac output and may be useful in high-risk patients. Four RCTs and a metaanalysis with patients undergoing major bowel surgery found that when intraoperative fluid administration was guided by transesophageal Doppler monitoring, there was a better ejection fraction, better oxygenation, and fewer postoperative complications. Although patients in these trials were not treated according to enhanced-recovery protocols, it seems that transesophageal Doppler monitoring enables optimization of intravascular volume and tissue perfusion in major abdominal surgery. In low-risk patients undergoing surgery of moderate magnitude, flow-guided therapy may not be warranted. High-grade evidence regarding the optimal regimen in terms of timing, type of fluid, and risk stratification is currently lacking."

Reference: Consensus Review of Optimal Perioperative Care in Colorectal Surgery Enhanced Recovery After Surgery (ERAS) Group Recommendations Arch Surg. 2009; 144(10):961-969. The guidelines were written in 2008 by influential clinicians from leading hospitals in Norway, Sweden, New Zealand, the Netherlands, Scotland, Germany and England.

Ewan Phillips, Deltex Medical's chief executive, commented:

"Recommendation by influential international groupings of eminent clinicians such as ERAS demonstrates the value of the uniquely powerful evidence base supporting the routine use of ODM during surgery. This publication is particularly timely in the UK where the Department of Health has embarked on the Enhanced Recovery Partnership Programme to define then roll-out evidence-based enhanced recovery care packages across all types of major surgery,

"We are confident that, as further positive clinical evidence is published, groups such as ERAS will expand further their recommended implementation of ODM both within colorectal surgery and in other surgical disciplines."

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Ewan Phillips, Chief Executive        [e-mail]

Paul Mitchell, Finance Director       [e-mail]

Nominated Adviser & Broker

Arden Partners plc                      020 7398 1600

Chris Hardie                                 [e-mail]

Matthew Armitt                             [e-mail]

Kreab Gavin Anderson                020 7554 1400

Deborah Walter                             [e-mail]

Robert Speed                                [e-mail]

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,750 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAZGMMMVVFGLZM